- Home
- CALT
as 07-26-2024 4:00pm EST
Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, initially focusing on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.
| Founded: | 2004 | Country: | Sweden |
| Employees: | N/A | City: | N/A |
| Market Cap: | 1.0B | IPO Year: | 2020 |
| Target Price: | $37.50 | AVG Volume (30 days): | 4.1K |
| Analyst Decision: | Hold | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.25 - $41.90 | Next Earning Date: | 08-15-2024 |
| Revenue: | $119,730,952 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 75.49% | Revenue Growth (next year): | 62.56% |
Latest Calliditas Therapeutics AB News
CALT Breaking Stock News: Dive into CALT Ticker-Specific Updates for Smart Investing
PR Newswire
10 hours ago
Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy
Clinical Trials Arena
14 hours ago
Calliditas’ Phase IIb trial of PBC treatment meets primary endpoint
MT Newswires
16 hours ago
Calliditas Therapeutics Says Liver Disease Therapy Met Main Goal in Phase 2b Study
PR Newswire
19 hours ago
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis
MT Newswires
22 days ago
Calliditas Therapeutics' Partner Launches Japanese Trial for IgA Nephropathy Treatment
PR Newswire
23 days ago
Launch of Phase 3 clinical trial with Nefecon in Japan
MT Newswires
a month ago
Calliditas Therapeutics Gets US Patent for Cancer Treatment Candidate
PR Newswire
a month ago
Calliditas provides setanaxib patent update
Compare CALT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CALT Calliditas Therapeutics AB - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.